LIFEVANTAGE CORP APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LIFEVANTAGE CORP (LFVN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.35 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-27
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $263.00K.
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $704.00K, a 53.71% decline year-over-year.
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $553.00K, a 67.89% decline year-over-year.
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $826.00K, a 9.92% decline year-over-year.
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $2.35M, a 58.86% decline from fiscal 2025.
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $5.70M, a 73.84% increase from fiscal 2024.
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.28M, a 2.89% increase from fiscal 2023.
- LIFEVANTAGE CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.19M, a 80.32% increase from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $263.00K derived: 10-K 12 month − 3 quarters · filed 2026-08-27 | $967.00K derived: sum of 2 quarters · filed 2026-08-27 | $1.52M derived: sum of 3 quarters · filed 2026-08-27 | $2.35M 10-K · filed 2026-08-27 |
| 2026-03-31 | $704.00K 10-Q · filed 2026-05-06 | $1.26M derived: sum of 2 quarters · filed 2026-05-06 | $2.08M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2025-12-31 | $553.00K 10-Q · filed 2026-05-06 | $1.38M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2025-09-30 | $826.00K 10-Q · filed 2026-05-06 | |||
| 2025-06-30 | $5.70M 10-K · filed 2026-08-27 | |||
| 2025-03-31 | $1.52M 10-Q · filed 2026-05-06 | $3.24M derived: sum of 2 quarters · filed 2026-05-06 | $4.16M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $1.72M 10-Q · filed 2026-05-06 | $2.64M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-09-30 | $917.00K 10-Q · filed 2026-05-06 | |||
| 2024-06-30 | $3.28M 10-K · filed 2025-09-04 | |||
| 2024-03-31 | $796.00K 10-Q · filed 2025-05-06 | $1.55M derived: sum of 2 quarters · filed 2025-05-06 | $2.52M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $750.00K 10-Q · filed 2025-05-06 | $1.73M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-09-30 | $978.00K 10-Q · filed 2025-05-06 | |||
| 2023-06-30 | $3.19M 10-K · filed 2024-08-28 | |||
| 2023-03-31 | $817.00K 10-Q · filed 2024-05-02 | $1.64M derived: sum of 2 quarters · filed 2024-05-02 | $2.24M derived: sum of 3 quarters · filed 2024-05-02 | |
| 2022-12-31 | $823.00K 10-Q · filed 2024-05-02 | $1.43M derived: sum of 2 quarters · filed 2024-05-02 | ||
| 2022-09-30 | $602.00K 10-Q · filed 2024-05-02 | |||
| 2022-06-30 | $1.77M 10-K · filed 2023-08-28 | |||
| 2022-03-31 | -$38.00K 10-Q · filed 2023-05-04 | $717.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.36M derived: sum of 3 quarters · filed 2023-05-04 | |
| 2021-12-31 | $755.00K 10-Q · filed 2023-05-04 | $1.40M derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2021-09-30 | $645.00K 10-Q · filed 2023-05-04 | |||
| 2021-06-30 | $2.15M 10-K · filed 2022-08-23 | |||
| 2021-03-31 | $684.00K 10-Q · filed 2022-05-03 | $1.68M derived: sum of 2 quarters · filed 2022-05-03 | $2.20M derived: sum of 3 quarters · filed 2022-05-03 | |
| 2020-12-31 | $999.00K 10-Q · filed 2022-05-03 | $1.52M derived: sum of 2 quarters · filed 2022-05-03 | ||
| 2020-09-30 | $520.00K 10-Q · filed 2022-05-03 | |||
| 2020-06-30 | $4.84M 10-K · filed 2022-08-23 | |||
| 2020-03-31 | $1.19M 10-Q · filed 2021-04-29 | $2.69M derived: sum of 2 quarters · filed 2021-04-29 | $3.97M derived: sum of 3 quarters · filed 2021-04-29 | |
| 2019-12-31 | $1.50M 10-Q · filed 2021-04-29 | $2.78M derived: sum of 2 quarters · filed 2021-04-29 | ||
| 2019-09-30 | $1.28M 10-Q · filed 2021-04-29 | |||
| 2019-06-30 | $4.90M 10-K · filed 2021-08-19 | |||
| 2019-03-31 | $2.01M 10-Q · filed 2019-05-01 | $3.00M derived: sum of 2 quarters · filed 2019-05-01 | $3.63M derived: sum of 3 quarters · filed 2019-05-01 | $4.31M derived: sum of 4 quarters · filed 2020-08-18 |
| 2018-12-31 | $999.00K 10-Q · filed 2019-05-01 | $629.00K 10-Q · filed 2019-02-04 | $2.31M derived: sum of 3 quarters · filed 2020-08-18 | $3.59M derived: sum of 4 quarters · filed 2020-08-18 |
| 2018-09-30 | $629.00K 10-Q · filed 2019-05-01 | $1.31M derived: sum of 2 quarters · filed 2020-08-18 | $2.59M derived: sum of 3 quarters · filed 2020-08-18 | $3.21M derived: sum of 4 quarters · filed 2020-08-18 |
| 2018-06-30 | $677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-18 | $1.96M derived: sum of 2 quarters · filed 2020-08-18 | $2.58M derived: sum of 3 quarters · filed 2020-08-18 | $2.99M 10-K · filed 2020-08-18 |
| 2018-03-31 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $1.91M derived: sum of 2 quarters · filed 2018-05-09 | $2.31M 10-Q · filed 2018-05-09 | $2.98M derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-12-31 | $620.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-07 | $1.03M 10-Q · filed 2018-02-07 | $1.69M derived: sum of 3 quarters · filed 2019-08-14 | $2.33M derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-09-30 | $408.00K 10-Q · filed 2017-11-08 | $1.07M derived: sum of 2 quarters · filed 2019-08-14 | $1.72M derived: sum of 3 quarters · filed 2019-08-14 | $2.05M derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-06-30 | $662.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-14 | $1.31M derived: sum of 2 quarters · filed 2019-08-14 | $1.64M derived: sum of 3 quarters · filed 2019-08-14 | $2.31M 10-K · filed 2019-08-14 |
| 2017-03-31 | $645.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | $978.00K derived: sum of 2 quarters · filed 2017-05-10 | $1.65M 10-Q · filed 2017-05-10 | $2.37M derived: sum of 4 quarters · filed 2018-08-15 |
| 2016-12-31 | $333.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | $1.01M 10-Q · filed 2017-02-08 | $1.73M derived: sum of 3 quarters · filed 2018-08-15 | $2.47M derived: sum of 4 quarters · filed 2018-08-15 |
| 2016-09-30 | $675.00K 10-Q · filed 2016-12-12 | $1.39M derived: sum of 2 quarters · filed 2018-08-15 | $2.14M derived: sum of 3 quarters · filed 2018-08-15 | $2.45M derived: sum of 4 quarters · filed 2018-08-15 |
| 2016-06-30 | $717.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-08-15 | $1.46M derived: sum of 2 quarters · filed 2018-08-15 | $1.78M derived: sum of 3 quarters · filed 2018-08-15 | $1.97M 10-K · filed 2018-08-15 |
| 2016-03-31 | $746.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-07-19 | $1.06M derived: sum of 2 quarters · filed 2016-07-19 | $1.25M 10-Q/A · filed 2016-07-19 | $1.55M derived: sum of 4 quarters · filed 2017-09-07 |
| 2015-12-31 | $315.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | $503.00K 10-Q · filed 2016-02-09 | $808.00K derived: sum of 3 quarters · filed 2017-09-07 | $1.38M derived: sum of 4 quarters · filed 2017-09-07 |
| 2015-09-30 | $188.00K 10-Q · filed 2015-11-04 | $493.00K derived: sum of 2 quarters · filed 2017-09-07 | $1.06M derived: sum of 3 quarters · filed 2017-09-07 | $1.53M derived: sum of 4 quarters · filed 2017-09-07 |
| 2015-06-30 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $875.00K derived: sum of 2 quarters · filed 2017-09-07 | $1.34M derived: sum of 3 quarters · filed 2017-09-07 | $1.74M 10-K · filed 2017-09-07 |
| 2015-03-31 | $570.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-06 | $1.03M derived: sum of 2 quarters · filed 2015-05-06 | $1.43M 10-Q · filed 2015-05-06 | $1.99M derived: sum of 4 quarters · filed 2016-12-12 |
| 2014-12-31 | $464.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-04 | $862.00K 10-Q · filed 2015-02-04 | $1.42M derived: sum of 3 quarters · filed 2016-12-12 | $2.02M derived: sum of 4 quarters · filed 2016-12-12 |
| 2014-09-30 | $398.00K 10-Q · filed 2014-11-06 | $960.00K derived: sum of 2 quarters · filed 2016-12-12 | $1.55M derived: sum of 3 quarters · filed 2016-12-12 | $2.24M derived: sum of 4 quarters · filed 2016-12-12 |
| 2014-06-30 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-12 | $1.15M derived: sum of 2 quarters · filed 2016-12-12 | $1.84M derived: sum of 3 quarters · filed 2016-12-12 | $2.61M 10-K · filed 2016-12-12 |
| 2014-03-31 | $591.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-06 | $1.28M derived: sum of 2 quarters · filed 2014-05-06 | $2.04M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $685.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-06 | $1.45M 10-Q · filed 2014-02-06 | ||
| 2013-09-30 | $768.00K 10-Q · filed 2013-11-07 | |||
| 2013-06-30 | $2.17M 10-K · filed 2015-09-01 | |||
| 2012-06-30 | $1.32M 10-K · filed 2014-09-10 | |||
| 2011-06-30 | $766.00K 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |